Provided is a vascular endothelial growth factor receptor (VEGFR2) resisting monoclonal antibody. The monoclonal antibody can be specifically combined the VEGFR2 and can block combination of a VEGF (vascular endothelial growth factor) and the VEGFR2; cell biology activity analysis shows that the VEGFR2 has remarkable inhibiting effect on VEGF-induced HUVEC (human umbilical vein endothelial cells); therefore, the VEGFR2 resisting monoclonal antibody can be applied to preparation of drugs capable of blocking the VEGFR2 to serve as a new anti-tumor drug.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
IAB-B066(A) | Recombinant Anti-human KDR Intrabody [(D-Arg)9] | FC, IF, FuncS | scFv-(D-Arg)9 |
IAB-B066(G) | Recombinant Anti-human KDR Intrabody [+36 GFP] | CO-IP, FuncS | scFv-(+36GFP) |
IAB-B066(T) | Recombinant Anti-human KDR Intrabody [Tat] | IF, ELISA, FuncS | scFv-Tat |
There are currently no Customer reviews or questions for HPAB-M0128-YC-S(P). Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.